Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 8/20 | 0.46 |
| ▸ | FNTB | P49356 | 8/20 | 0.46 |
| ▸ | NMT2 | O60551 | 1/20 | 0.43 |
| ▸ | NMT1 | P30419 | 1/20 | 0.43 |
| ▸ | FURIN | P09958 | 4/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.41 |
| ▸ | PCSK6 | P29122 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4810020 | 1.00 | FNTA (0.46) | FNTAFNTBNMT2NMT1FURIN | |
| SCHEMBL29551013 | 0.89 | NMT2 (0.43) | FNTAFNTBNMT2NMT1 | |
| SCHEMBL29630586 | 0.88 | CPB2 (0.47) | FNTAFNTBNMT2NMT1FURIN | |
| SCHEMBL31319511 | 0.88 | NMT2 (0.44) | FNTAFNTBNMT2NMT1CPB2 | |
| SCHEMBL29386095 | 0.88 | GSR (0.45) | NMT2NMT1CPB2 | |
| SCHEMBL31722954 | 0.88 | NMT1 (0.43) | NMT2NMT1CPB2 | |
| SCHEMBL30123480 | 0.88 | FNTA (0.50) | FNTAFNTB | |
| SCHEMBL29473686 | 0.87 | NMT2 (0.47) | NMT2NMT1FURINCPB2PCSK6 | |
| SCHEMBL31514345 | 0.87 | FNTA (0.47) | FNTAFNTBFURINCPB2 | |
| SCHEMBL28435814 | 0.87 | FOLH1 (0.47) | FNTAFNTBNMT2NMT1CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7344851-B2 | Anticancer agents based on prevention of protein prenylation | ARIZONA BIOMEDICAL RESEARCH COMMISSION (US) | 2008-03-18 | — | — | US | disclosed |
| US-7012097-B2 | Anticancer agents based on prevention of protein prenylation | THE ARIZONA DISEASE CONTROL RESEARCH COMMISSION (US) | 2006-03-14 | — | — | US | disclosed |
| US-20060030624-A1 | Alpha-Dicarbonyl compounds can be used to covalently modify and thereby inactivate prenylating enzymes such as protein farnesyltransferase and protein geranylgeranyltransferase; drug screening; antitumor agents; antiproliferative agents | ARIZONA DISEASE CONTROL RESEARCH COMMISSION (US) | 2006-02-09 | — | — | US | disclosed |
| US-20030219847-A1 | Anticancer agents based on prevention of protein prenylation | THE ARIZONA DISEASE CONTROL RESEARCH COMMISSION | 2003-11-27 | — | — | US | disclosed |
| US-6576436-B1 | Inactivating farnesyltransferase using a alpha-dicarbonyl compound of given formula; drug screening; antitumor agents; antiproliferative agents | THE ARIZONA DISEASE CONTROL RESEARCH COMMISSION | 2003-06-10 | — | — | US | disclosed |
| WO-2000033826-A1 | ANTICANCER AGENTS BASED ON PREVENTION OF PROTEIN PRENYLATION | THE ARIZONA DISEASE CONTROL RESEARCH COMMISSION (US) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030219847-A1 | Anticancer agents based on prevention of protein prenylation | RCE1, FNTA, FNTB | FNTA 2/4885FNTB 3/4885NMT2 149/4885 |
| US-20060030624-A1 | Alpha-Dicarbonyl compounds can be used to covalently modify and thereby inactivate prenylating enzymes such as protein farnesyltransferase and protein geranylgeranyltransferase; drug screening; antitumor agents; antiproliferative agents | FNTA, FNTB, RCE1 | FNTA 1/4885FNTB 2/4885NMT2 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.